Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
2-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly
similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine
(MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic,
hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the
serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A
receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its
reported mixed effects profile. However, scientific studies are lacking. There is an
increased interest in psychiatric research on the therapeutic properties of MDMA and
psilocybin and also on mixed empathogenic-psychedelic substances.